For research teamsHelp me find a study
Back to all studies
RecruitingEUCTR 2022-001906-24

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial .

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

ADHD, Children, Adolescents, Under 18Drug
In plain English

Key information made simple

What the source confirms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View the historical EU CTR record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Medical University in Lodz
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Poland
Age range
Not clearly listed
Official registry ID
EUCTR 2022-001906-24
Official title
LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial .

Want help reviewing this study?

Loading the security check...
Study ID: EUCTR 2022-001906-24. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

View the historical EU CTR record (opens in a new tab)View the current CTIS record (opens in a new tab)
Current CTIS country statuses
Historical EU CTR country statuses
  • Poland : Trial now transitioned

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Poland · 5 sites
  • Uniwersyteckie Centrum Kliniczne — Klinika pediatrii, diabetologii i endokrynologii
    Gdansk
    Site status: Not listed — confirm with the team
  • Medical University Of Silesia Katowice Poland — Klinika Diabetologii Dziecięcej
    Katowice
    Site status: Not listed — confirm with the team
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W Lodzi — Klinika Pediatrii, Diabetologii, Endokrynologii i Nefrologii Uniwersytetu Medycznego w Łodzi
    Lodz
    Site status: Not listed — confirm with the team
  • Uniwersytecki Szpital Kliniczny W Opolu — Klinika pediatrii
    Opole
    Site status: Not listed — confirm with the team
  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego — Oddział Kliniczny Diabetologii Dziecięcej i Pediatrii
    Warsaw
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Is this study recruiting?

The public registry lists this study as recruiting. Individual sites may have different statuses. The research team must confirm whether a site is open and whether you meet the criteria.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.